Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

Condition(s) studied

Investigational drug(s) / intervention(s)

postoperative adjuvant therapy: Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Study summary

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Eligibility

Primary outcome measure(s)

• Disease-free survival — From December 2018 to May 2023
  Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.

Trial sites (1)

More West China Hospital trials in China

Other trials for the same condition